Fig. 5.

Cetuximab-coated tumor cells with ALT-803-stimulated NK cells enhance T cell chemotaxis. Cal27 tumor cells were treated with 100 μg/ml of cetuximab or control IgG and the indicated stimulus (IL-15 or ALT-803) for 1 h at 37 °C. Purified healthy donor CD56⁺ human NK cells were co-cultured with tumor cells (cetuximab or control IgG) for 48 h and supernatants assayed for a RANTES and b IL-8 by ELISA. Representative of 3 donors; *P < 0.05 compared to NK cells; ^#P < 0.05 compared to NK cells + tumor cells. c Supernatants from NK cells and tumor cell co-cultures from media control, tumor cells alone, IgG-coated tumor cells, and cetuximab-coated tumor cells were plated in the bottom of a transwell and a filter was placed above which contained autologous isolated healthy donor CD3⁺ T cells. After 4 h, the number of T cells migrating to bottom well was quantified by flow cytometric analysis. Means + STD of 3 donors; *P < 0.05 compared to NK cells; ^#P < 0.05 compared to NK cells + tumor cells